Skip to main content

Table 4 Mean change in PETiT assessments by discontinuation status among patients switched to lurasidone

From: Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia

 

Parameter

All patients

Sedating

Non-sedating

Discontinued*

Completed

Discontinued*

Completed

Discontinued*

Completed

(n = 37)

(n = 198)

(n = 18)

(n = 65)

(n = 19)

(n = 133)

PETiT total score

Baseline (SD)

34.3 (7.6)

35.1 (9.0)

33.2 (6.9)

33.9 (9.0)

35.4 (8.3)

35.7 (9.0)

LOCF (SD)

33.7 (11.0)

39.1 (8.9)

30.9 (11.5)

37.5 (9.6)

36.8 (10.0)

39.8 (8.4)

Mean change (SD)

-3.6 (12.4)

4.0 (7.7)

-4.5 (14.7)

3.9 (7.5)

-2.6 (9.9)

4.0 (7.8)

p-value**

< 0.001

0.008

0.004

Adherence-related attitude domain score (6 items)

Baseline (SD)

8.7 (1.7)

8.7 (2.1)

8.6 (1.2)

8.3 (2.2)

8.7 (2.2)

8.8 (2.1)

LOCF (SD)

8.0 (3.4)

9.6 (2.0)

7.4 (3.7)

9.1 (2.2)

8.6 (3.2)

9.8 (1.9)

Mean change (SD)

-1.4 (3.4)

0.9 (2.4)

-1.6 (4.2)

0.8 (2.3)

-1.1 (2.6)

1.0 (2.4)

p-value**

 

< 0.001

 

0.003

 

0.010

Psychosocial functioning domain score (24 items)

Baseline (SD)

25.6 (6.9)

26. 5 (7.9)

24.6 (6.5)

25.6 (7.9)

26.6 (7.2)

26.9 (7.9)

LOCF (SD)

25.8 (8.2)

29.5 (7.8)

23.5 (8.5)

28.4 (8.4)

28.2 (7.4)

30.0 (7.5)

Mean change (SD)

-2.2 (9.7)

3.0 (6.3)

-2.9 (11.3)

3.0 (6.2)

-1.5 (8.2)

3.1 (6.4)

p-value**

< 0.001

0.028

0.011

  1. *Subjects who discontinued treatment with lurasidone due to any reason.
  2. **Comparison of mean change between subjects who discontinued versus completed treatment with lurasidone at 6-week endpoint.
  3. Note: preswitch sedating medications include quetiapine and olanzapine; preswitch non-sedating medications include risperidone, aripiprazole, and ziprasidone.